Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Part 1 and 2 Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

NCT04844424

View directory record Official record

Conditions: Healthy
Interventions: Milvexian; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Source: ClinicalTrials.gov public record

Updated May 22, 2025 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229

View directory record Official record

Conditions: Healthy Participants
Interventions: BMS-986365, Rabeprazole; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only

Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Source: ClinicalTrials.gov public record

Updated Mar 5, 2025 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666

View directory record Official record

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Aug 24, 2015 · Synced May 22, 2026, 1:39 AM EDT

Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006

View directory record Official record

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri

Source: ClinicalTrials.gov public record

Updated Feb 19, 2026 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

NCT06385119

View directory record Official record

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Mar 26, 2026 · Synced May 22, 2026, 1:39 AM EDT

Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692

View directory record Official record

Conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions: Vodobatinib (K0706) capsules; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older

Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701

View directory record Official record

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Source: ClinicalTrials.gov public record

Updated Apr 3, 2023 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767

View directory record Official record

Conditions: Relapsed or Refractory Lymphoma
Interventions: HMPL-523, Itraconazole, Rifampin; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Feb 28, 2023 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

NCT03601637

View directory record Official record

Conditions: Cystic Fibrosis
Interventions: LUM, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Months to 23 Months

Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more

Source: ClinicalTrials.gov public record

Updated Jan 5, 2023 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

NCT06895356

View directory record Official record

Conditions: Healthy Volunteer
Interventions: Tavapadon; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Source: ClinicalTrials.gov public record

Updated Jun 25, 2025 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

NCT02359045

View directory record Official record

Conditions: Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions: D1400147, D14000136, D14000137, Epanova®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only

Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Apr 30, 2017 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

NCT06270511

View directory record Official record

Conditions: Healthy Volunteers
Interventions: S-337395, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lenexa, Kansas

Source: ClinicalTrials.gov public record

Updated Jul 9, 2024 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Food and Age on Danicopan

NCT04551599

View directory record Official record

Conditions: Healthy
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Source: ClinicalTrials.gov public record

Updated Jan 12, 2023 · Synced May 22, 2026, 1:39 AM EDT

Recruiting Phase 1Phase 2 Interventional

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

NCT06600789

View directory record Official record

Conditions: Solid Malignancies
Interventions: CT7439 Capsules (0.5 mg, 1mg, 3mg); Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older

Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Dallas, Texas • San Antonio, Texas • Fairfax, Virginia

Source: ClinicalTrials.gov public record

Updated Nov 2, 2025 · Synced May 22, 2026, 1:39 AM EDT

Recruiting Phase 1 Interventional

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908

View directory record Official record

Conditions: Advanced Solid Tumor
Interventions: M3554; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 2Phase 3 Interventional

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390

View directory record Official record

Conditions: Hemophilia A, Hemophilia B
Interventions: BAY86-6150, eptacog alfa [activated]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 62 Years · Male only

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Sacramento, California • Chattanooga, Tennessee

Source: ClinicalTrials.gov public record

Updated Jun 30, 2015 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

NCT06846866

View directory record Official record

Conditions: Healthy Volunteers
Interventions: BMS-986419, BMS-986419 Matching Placebo, Moxifloxacin, Moxifloxacin Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Source: ClinicalTrials.gov public record

Updated Nov 16, 2025 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

NCT04720443

View directory record Official record

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: NIP292 tablet, NIP292 tablets; Drug
Lead sponsor: The National Institutes of Pharmaceutical R&D Co. Ltd, China; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Mar 23, 2023 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1

NCT00392015

View directory record Official record

Conditions: Plasmodium Falciparum
Interventions: NMRC-M3V-Ad-PfCA, NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years

Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated May 20, 2021 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435

View directory record Official record

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Source: ClinicalTrials.gov public record

Updated Oct 7, 2020 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205

View directory record Official record

Conditions: Healthy Adults
Interventions: PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Aug 18, 2024 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

NCT02307461

View directory record Official record

Conditions: Healthy
Interventions: IPI-145 (duvelisib), IPI-145; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lenexa, Kansas

Source: ClinicalTrials.gov public record

Updated Mar 16, 2021 · Synced May 22, 2026, 1:39 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781

View directory record Official record

Conditions: Healthy Volunteers
Interventions: BMS-986365, Itraconazole, Rifampin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only

Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Dec 23, 2025 · Synced May 22, 2026, 1:39 AM EDT

Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329

View directory record Official record

Conditions: Neoplasms, Breast
Interventions: lapatinib, lapatinib plus esomeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Greenville, South Carolina

Source: ClinicalTrials.gov public record

Updated Nov 13, 2017 · Synced May 22, 2026, 1:39 AM EDT